Premium on Momentum, Not on Stability
ALNY trades as a rare-disease growth story, not a defensive pharma. The market reads 96.4% revenue growth as momentum, but 46.2% volatility means any slip hits hard. Even a single weak quarter can spark a sharp selloff. Too risky for a premium biotech.
Published by AssetNext · 2026-06-13
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-20 | Quality under pressure | 63 | -44.5% | -17.0% |
| 2026-07-14 | Quality under pressure | 62 | -42.7% | -15.7% |
| 2026-07-10 | Quality under pressure | 61 | -39.2% | -12.7% |
| 2026-06-30 | Gap to peers | 64 | -38.7% | -4.2% |
| 2026-06-26 | Quality under pressure | 62 | -40.7% | -14.7% |
Break down ALNY's structural position across all peer dimensions with the interactive app.